CN1743326A - Carboline carboxylate derivative, and its synthesizing method and use - Google Patents
Carboline carboxylate derivative, and its synthesizing method and use Download PDFInfo
- Publication number
- CN1743326A CN1743326A CN 200410074204 CN200410074204A CN1743326A CN 1743326 A CN1743326 A CN 1743326A CN 200410074204 CN200410074204 CN 200410074204 CN 200410074204 A CN200410074204 A CN 200410074204A CN 1743326 A CN1743326 A CN 1743326A
- Authority
- CN
- China
- Prior art keywords
- lin
- tetrahydrochysene
- carboxylic acid
- preparation
- boc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007942 carboxylates Chemical class 0.000 title claims description 26
- 230000002194 synthesizing effect Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 62
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 11
- 230000002785 anti-thrombosis Effects 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 59
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 12
- 238000010189 synthetic method Methods 0.000 claims description 10
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
- -1 amino acid ester Chemical class 0.000 claims description 7
- 229960004799 tryptophan Drugs 0.000 claims description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 238000007127 saponification reaction Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 238000007171 acid catalysis Methods 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 230000000702 anti-platelet effect Effects 0.000 abstract description 3
- 150000001735 carboxylic acids Chemical class 0.000 abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 239000007787 solid Substances 0.000 description 41
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 38
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 241000304531 Allium macrostemon Species 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 239000006035 Tryptophane Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- 244000295724 Allium chinense Species 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- 235000016790 Allium chinense Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 244000241257 Cucumis melo Species 0.000 description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241001494508 Arundo donax Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- LPIJOZBIVDCQTE-MRVPVSSYSA-N Calligonine Chemical compound N1C2=CC=CC=C2C2=C1[C@@H](C)NCC2 LPIJOZBIVDCQTE-MRVPVSSYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 235000017643 Elaeagnus angustifolia Nutrition 0.000 description 1
- 244000016119 Elaeagnus latifolia Species 0.000 description 1
- 235000001456 Elaeagnus latifolia Nutrition 0.000 description 1
- 235000007630 Elaeagnus umbellata var parvifolia Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 244000186402 Phyllodium pulchellum Species 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention discloses a new series of derivatives of carboline carboxylic acid, their preparation method, as well as their use. The derivative is prepared by introducing amino acid to carboline carboxylic acid's lateral chain. As confirmed in experiment, these derivatives possess high solubility, high antithrombotic activity and anti-platelet aggregation. activity.
Description
Technical field
The present invention relates to a kind of carboline carboxylate derivative, relate in particular to a kind of carboline carboxylate derivative and preparation method thereof with antithrombotic acitivity.
Background technology
Be that the sickness rate of cardiovascular disorder of representative is in rising trend with cardiovascular embolism and cerebral vessels embolism in recent years, serious harm health.The number that the U.S. in 1998 dies from cardiovascular disorder is than the lethal total number of persons of cancer, traffic accident and acquired immune deficiency syndrome (AIDS) also many (Heart and Stroke A-Z Guide:2001 Heart andStroke Statistical Update.Available at:http: //www.americanheart.org.AccessedMay 2001).Atherosclerosis, myocardial infarction, cerebral infarction and pulmonary infarction are all closely related with the formation of thrombus.Some other disease or symptom, as all relevant (Li Jiazeng, He Shilin, Wang Hongli chief editor such as diabetes, kidney disease, hepatic diseases, hemopathy, systemic lupus erythematous, malignant tumour, burn, wound, surgical operation, hemodialysis, cardiac surgery, organ transplantation, gestation, newborn infant's sudden deafness, ophthalmic diseases, thromboangiitis obliterans and disseminated inravascular coagulation with the formation of thrombus, " thrombus disease ", Science Press, 1998).
1,2,3,4-tetrahydrochysene-β-Ka Lin is the parent nucleus that extensively is present in the many important indole alkaloid in the medicinal plant.For example 1,2,3,4-tetrahydrochysene-β-Ka Lin is the N in the giantreed
bThe banisterine of 6-methoxyl group-tetrahydrochysene-β-Ka Lin among-methyltetrahydroharman, the Desmodiumpulchellum Benth er Barker and 6-methoxytetraphydroharman, oleaster and the parent nucleus (Lin Qishou etc. of elaeagnine and 1-isobutyl-tetrahydrochysene-β-Ka Lin etc., the medicinal herb components chemistry, Science Press, 1997).Because 1,2,3,4-tetrahydrochysene-β-Ka Lin has tangible anti-platelet activity, so become the medicine guide structure type of extremely paying attention to, carboline carboxylate is one of them typical case's representative.
The Chinese medicine Longstamen Onion Bulb is the dry bulb of Liliaceae allium Allium macrostemon (Allium macrostemon Bunge) or Chinese onion (A.chinense G.Don).Allium macrostemon originates in ground such as northeast, North China, records in Chinese Pharmacopoeia 1990 editions.Chinese onion originates in China south.Longstamen Onion Bulb cures mainly diseases such as " obstruction of qi in the chest ", " chesting pain radiating to the back ".The obstruction of qi in the chest is equivalent to stenocardia and myocardial infarction with chesting pain radiating to the back.Longstamen Onion Bulb is contained in some sides that the Han dynasty Zhang Zhongjing proposes, and for example " melon withers, Longstamen Onion Bulb liquor soup ", " melon withers, Longstamen Onion Bulb, tuber of pinellia soup " and " dried immature fruit of citron orange, Longstamen Onion Bulb, cassia twig soup " etc. are all contained Longstamen Onion Bulb.In the anti-platelet activity screening, Bulbus Allii Macrostemonis extract shows strong active.(Yao new life etc. derive from several nitrogenous compounds in Allium macrostemon and the Chinese onion to the platelet aggregation inhibitory activity of (the S)-carboline carboxylate that is separated to from Longstamen Onion Bulb for Peng Junpeng, Qiao Yanqiu than the strong several times of acetylsalicylic acid.China's pharmaceutical chemistry magazine, May nineteen ninety-five, 134).What the traditional Chinese medical science had a doctor food homology says that promptly some medicines also are food.Chinese Government is formal announce not only can be used as medicine but also can be used as in the inventory of food and comprised the face Longstamen Onion Bulb.As seen, Longstamen Onion Bulb is foolproof simply Chinese medicine.Carboline carboxylate from Longstamen Onion Bulb is foolproof compound.Verified (S)-carboline carboxylate is as the potential significance of antithrombotic reagent elder generation guide structure (Peng Shiqi etc., Tetrahydrocarboline carboxylic acid and RGD conjugate thereof, they synthetic and at medically application, Chinese patent, application number: 01144616.6).
But the solubleness extreme difference of carboline carboxylate is dissolved in any solvent hardly, causes its bioavailability extreme difference thus.This shortcoming has seriously limited its application on food and medicine.
Summary of the invention
Technical problem to be solved by this invention provides a class solubleness height, carboline carboxylate derivative that antithrombotic acitivity is high.
Another technical problem to be solved by this invention provides the preparation method of this carboline carboxylate derivative.
Technical problem to be solved by this invention realizes by following approach:
The invention provides a kind of carboline carboxylate derivative, have the structure of general formula I.
General formula I
Wherein R is selected from-CH
3, CH
2C
6H
5,-CH (CH
3)
2,-CH
2OH ,-CH (OH) CH
3,-CH
2C
6H
4-OH-p, Pyrrolidine-2-base ,-CH
2SH ,-CH
2CH
2SCH
3,-CH
2CH
2COOH ,-CH
2COOH, 1,3-imidazoles methyl or indoles-3-methyl.
Another technical problem to be solved by this invention provides the preparation method of above-mentioned compound of Formula I, and the synthetic method of this compound of Formula I may further comprise the steps:
1, L-tryptophane and formaldehyde condensation are made (3S)-β-Ka Lin carboxylic acid,
2,2 N to (3S)-β-Ka Lin carboxylic acid protect, and prepare N-protected base-β-Ka Lin carboxylic acid,
3, with N-protected base-β-Ka Lin carboxylic acid and amino acid ester condensation prepared N-protected base-β-Ka Lin amido-carboxylic acid esters,
4, N-protected base-β-Ka Lin amido-carboxylic acid esters is taken off protecting group and ester is hydrolyzed to acid promptly gets general formula compound of the present invention.
In the above-mentioned synthetic method, wherein the condensation reaction in the step 1 is to carry out under mineral acid catalysis, is preferably the vitriol oil; Wherein the protecting group of 2 N of (3S)-β-Ka Lin carboxylic acid both can be that tertbutyloxycarbonyl can be a benzyl also in the step 2, was preferably tertbutyloxycarbonyl; Condensing agent in the step 3 is preferably DCC (dicyclohexyl carbodiimide); Wherein deprotection and ester hydrolysing step can be first saponification hydrogenolysis or first saponification acidolysis more again in the step 4, are preferably first saponification acidolysis again;
Amino acid is proteinic basic structural unit, extensively is present in the organism, and normal physiological function has and important effect to keeping.Because amino acid has acid, alkali amphoteric unique texture, so can be used for the structural modification of drug molecule, can improve the interaction of drug molecule and acceptor by amino acid.
The present invention introduces amino acid at the side chain of carboline carboxylate, can obviously improve the pharmacokinetic property of carboline carboxylate, can improve the solubility property of carboline carboxylate on the one hand, also can improve the absorption and the transhipment of carboline carboxylate on the other hand, thereby can significantly improve the antithrombotic acitivity of carboline carboxylate.
Description of drawings
The synthetic route of the carboline carboxylate that Fig. 1 is amino acid modified
Embodiment
Specify the present invention below with reference to embodiment, embodiments of the invention only are used to technical scheme of the present invention is described, and non-limiting scope of the present invention.
The preparation of The compounds of this invention intermediate
One, 1,2,3, the preparation of 4-tetrahydrochysene-β-Ka Lin-3-carboxylic acid
0.18ml diluting concentrated sulfuric acid in 400ml water, adds 5g (22.4mmol) Trp (tryptophane) then.Treat that Trp dissolves the back fully and adds 10ml formaldehyde, room temperature reaction is after 6 hours, and the TLC plate shows that raw material disappears, and adds the pH to 8-9 of 10ml ammoniacal liquor (2.5%) conditioned reaction thing.Reaction mixes leaves standstill suction filtration after 30 minutes, and the white solid that obtains gets 4.6g (95.1%) title compound with ethanol, water, ammoniacal liquor recrystallization, is white solid.
Two, N-Boc-1,2,3, the preparation of 4-tetrahydrochysene-β-Ka Lin-3-carboxylic acid
The following 1g of ice bath (4.17mmol) 1,2,3,4-tetrahydrochysene-β-Ka Lin-3-carboxylic acid is suspended in 1.1g (Boc)
2In the solution that O (tertiary butyloxycarbonyl acid anhydride) and 10ml DMF (dimethyl formamide) make.The solution that obtains adds 1.5ml triethylamine adjust pH 8-9.The reaction mixture ice bath stirs 4h down.In the reaction process 2,3,4,9-tetrahydrochysene-β-Ka Lin-3-carboxylic acid dissolves gradually, and TLC (chloroform/methanol/Glacial acetic acid: 5: 3: 0.4) shows raw material point disappearance.Concentrating under reduced pressure removes and to desolvate, residue with acetic acid ethyl dissolution after, use 5%KHSO successively
4, saturated NaCl washes, and the organic layer anhydrous sodium sulfate drying filters, concentrating under reduced pressure, residue washs with chloroform, obtains 1g (68%) title compound.
The preparation of [embodiment 1] N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) L-Ala (5a)
The preparation of step 1, N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-alanine methyl ester (3a)
2g (6.33mmol) N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-carboxylic acid is dissolved among the anhydrous THF of 30ml, adds 1.2g (8.9mmol) N-hydroxy benzo triazole (HOBt) under the ice bath inward, adds 1.75g (8.5mmol) DCC after 10 minutes inward.1.07g (6.96mmol) HClAlaOMe (alanine methyl ester hydrochloride) is suspended among the anhydrous THF of 3ml, adds the 1ml N-methylmorpholine then and regulates pH to 8-9, reacts 20 minutes.After 10 minutes this solution is added in the top solution that contains the N-hydroxy benzo triazole.The reaction mixture stirred overnight at room temperature, TLC (chloroform/methanol, 15: 1) shows that raw material point disappears, and leaches DCU (dicyclohexylurea (DCU)), filtrate decompression is concentrated into dried, the residue acetic acid ethyl dissolution.The solution that obtains is used saturated NaHCO successively
3, saturated NaCl, 5%KHSO
4, saturated NaCl, saturated NaHCO
3, saturated NaCl is washed till neutrality, anhydrous Na
2SO
4Dry.Filter, be evaporated to dried, 2.6g (%) title compound, be faint yellow solid.Rf=0.383 (chloroform/methanol, 15: 1)
Step 2, N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) preparation of L-Ala (4a)
1.0g (2.5mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-carbamino alanine methyl esters is dissolved in the mixed solvent of 4ml methyl alcohol and 2ml chloroform, ice bath adds 0.45g (11.34mmol) NaOH down, it is yellow that reaction solution graduates into, TLC after 70 minutes (chloroform/methanol, 30/1) demonstration reacts completely, and concentrating under reduced pressure boils off solvent, residue adds the 30ml water dissolution, use ethyl acetate extraction, water layer is transferred pH value with 4NHCl under ice bath be 1-2, separates out yellow oil, ethyl acetate extraction, anhydrous Na
2SO
4Drying, filtration, concentrating under reduced pressure get title compound 750mg (79%), are faint yellow solid.
The preparation of step 3, N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) L-Ala (5a)
Ice bath is down toward 700mg (1.85mmol) N-[(2-N-Boc-1; 2; 3; 4-tetrahydrochysene-β-Ka Lin-3-formyl radical) adds 8ml HCl-ethyl acetate (4N) in the solution of L-Ala and 8ml anhydrous ethyl acetate; Stir mixes TLC (chloroform/methanol after 60 minutes; 5/1) show that raw material point disappears, reaction solution is evaporated to dried, adds the 10ml ethyl acetate in the residue that obtains; be evaporated to dried again; this operation three times repeatedly, the residue that obtains adds the 20ml ethyl acetate, grinds; filter; solid gets title compound 500mg (86%) with propyl carbinol-ether recrystallization, is the reddish-brown powder.ESI/MS:288[M+H]
+,
(C=1.0,DMF)
1HNMR(300MHZ,DMSO-d6):δ/ppm=1.378(d,J=6.6Hz,3H,),2.887(s,1H),2.930(s,1H),3.371(s,1H),4.275(m,1H),4.356(m,2H),4.481(m,1H),7.031(s,1H),7.120(s,1H),7.382(d,J=7.8Hz,1H),7.469(d,J=6.6Hz,1H),9.022(s,1H),9.861(s,1H),11.186(s,1H).
The preparation of embodiment 2 N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) phenylalanine (5b)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-phenylalanine methyl ester (3b)
Adopt the operation of step 1 among the embodiment 1, from 1g (3.16mmol) N-Boc-1,2,3, suspension and the 0.6ml N-methylmorpholine of 4-tetrahydrochysene-β-Ka Lin-3-carboxylic acid, the anhydrous THF of 15ml, 0.6g (4.45mmol) HOBt, 0.87g (4.3mmol) DCC, 0.75g HClPheOMe (3.48mmol) and the anhydrous THF of 3ml get 1.5g (%) title compound, are faint yellow solid.ESI/MS:478[M+H]
+,378[M+H-Boc]
+。Rf=0.4 (chloroform/methanol, 15: 1)
2, the preparation of phenylalanine (4b) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)
Adopt the operation of step 2 among the embodiment 1, by 900mg (1.89mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl phenylalanine methyl ester obtains 650mg (74.5%) title compound, is faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) phenylalanine (5b)
Adopting the operation of step 3 among the embodiment 1, by 600mg (1.3mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) phenylalanine obtains 490mg (95%) title compound, is the reddish-brown solid.ESI/MS:364[M+H]
+,
(C=1, ethanol),
1HNMR (300MHZ, DMSO-d6): δ/ppm=1.277-1.412 (m, 2H), 2.988 (m, 2H), 3.216 (m, 1H), 4.188 (m, 2H), 4.656 (m, 1H), 7.012 (s, 1H), 7.122 (s, 1H), 7.204 (t, J=6.8Hz, 1H), 7.380 (d, J=7.8Hz1H), 7.384 (d, J=7.6Hz, 2H), 7.464 (d, J=6.4Hz, 1H), 7.467 (t, J=6.8Hz, 2H), 9.012 (d, J=7.8Hz, 1H), 9.813 (s, 1H), 11.133 (s, 1H).
The preparation of embodiment 3.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Xie Ansuan (5c)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-valine methyl ester (3c)
Adopt the operation of step 1 among the embodiment 1, from 1g (3.16mmol) N-Boc-1,2,3, suspension and the 0.6ml N-methylmorpholine of 4-tetrahydrochysene-β-Ka Lin-3-carboxylic acid, the anhydrous THF of 15ml, 0.6g (4.45mmol) N-hydroxy benzo triazole, 0.87g (4.3mmol) DCC, 0.58g HClVal-Ome (3.48mmol) and the anhydrous THF of 3ml get 1.3g (%) title compound, are faint yellow solid.ESI/MS:452[M+Na]
+,430[M+H]
+。IR (cm
-1): 3412,1691,1455,1511,1622,1383,741.Rf=0.417 (chloroform/methanol, 15: 1)
2, the preparation of N-(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Xie Ansuan (4c)
Adopt the operation of step 2 among the embodiment 1, by 0.75g (1.75mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl valine methyl ester obtains 0.515g (71%) title compound, is faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Xie Ansuan (5c)
Adopting the operation of step 3 among the embodiment 1, by 600mg (1.3mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Xie Ansuan obtains 380mg (95%) title compound, is faint yellow solid.Mp169℃-171℃,ESI/MS:316[M+H]
+,
(C=1,DMF),
1HNMR(300MHZ,DMSO-d6):δ/ppm=0.938(d,J=6.9Hz,3H),0.971(s,3H),2.166(dd,J=6.9Hz,J=5.7Hz,1H),2.849(d,J=5.4Hz,1H),3.153-3.381(m,J=4.9Hz,1H,),4.230(s,2H),4.337(s,1H),4.479(m,2H),7.013(t,J=7.2Hz,1H),7.104(t,J=7.4Hz,1H);7.366(d,J=7.8Hz,1H),7.462(d,J=7.5Hz,1H),8.787(s,1H),9.824(s,1H),11.190(s,1H),12.680(s,1H)。
The preparation of embodiment 4.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Serine (5d)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-serine methylester (3d)
Adopt the operation of step 1 among the embodiment 1, replace 1.07g (6.96mmol) HClAlaOMe 2g (6.33mmol) to get 2.6g (%) title compound, be faint yellow solid with 1.08g (6.96mmol) HClSerOMe.ESI/MS:419.1[M+H]
+, Rf=0.267 (chloroform/methanol, 15: 1)
2, the preparation of Serine (4d) N-[(2-N-Boc-1,2,3,4--tetrahydrochysene-β-Ka Lin-3-formyl radical)
Adopt the operation of step 2 among the embodiment 1, by 1.3g (3.12mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl serine methylester obtains 1.05g (84%) title compound, is faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Serine (5d)
Adopting the operation of step 3 among the embodiment 1, by 1.05g (2.6mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Serine obtains 700mg (85%) title compound, is the reddish-brown solid.ESI/MS:304[M+H]
+,
(C=1,DMF),
1HNMR(300MHZ,DMSO-d6):δ/ppm=2.896(d,J=6.9Hz,1H),3.407(m,J=5.4Hz,1H),3.779(d,J=4.5Hz,2H),4.305(t,J=4.9Hz,1H),4.455(m,J=5.1Hz,2H),4.489(s,1H),7.122(t,J=7.8Hz,1H),7.384(d,J=7.8Hz,1H),7.468(d,J=7.5Hz,1H),9.104(d,J=7.2Hz,1H),9.861(s,1H),11.190(s,1H),12.9(s,1H)。
The preparation of embodiment 5.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Threonine (5e)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-Threonine methyl esters (3e)
Adopt the operation of step 1 among the embodiment 1, replace 1.07g (6.96mmol) HClAlaOMe 2g (6.33mmol) to get the 2.7g title compound, be faint yellow solid with 1.08g (6.96mmol) HClThrOMe oily matter.Rf=0.267 (chloroform/methanol, 15: 1)
2, the preparation of N-(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-Threonine (4e)
Adopt the operation of step 2 among the embodiment 1, by 1g (2.32mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl Threonine methyl esters obtains 750mg (78%) title compound, is faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Threonine (5e)
Adopting the operation of step 3 among the embodiment 1, by 750mg (1.8mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Threonine obtains 580mg (91%) title compound, is the reddish-brown solid.Mp180℃-182℃,ESI/MS:318[M+H]
+,
(C=1, ethanol), IR (cm
-1): 3378,2976,1677,747,
1HNMR (300MHZ, DMSO-d6): δ/ppm=2.873 (t, J=5.5Hz 1H), 3.451 (m, J=5.4Hz, 1H), 4.230 (m, J=5.4Hz, 1H), 4.355 (m, J=6.4Hz, 2H) 4.448 (s, 1H), 5.316 (s, 1H), 7.028 (t, J=7.8Hz, 1H), 7.121 (t, J=8.4Hz, 1H), 7.384 (dJ=8.1Hz, 1H), 7.463 (d, J=7.5Hz, 1H), 8.951 (d, J=8.4Hz, 1H), 9.861 (m, 1H) 11.223 (d, J=4.2Hz, 1H), 12.9 (s, 1H).
The preparation of embodiment 6.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) tyrosine (5f)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-L-Tyrosine methyl ester (3f)
Adopt the operation of step 1 among the embodiment 1, replace 1.07g (6.96mmol) HClAlaOMe 2g (6.33mmol) to get the 3.2g title compound, be faint yellow solid with 1.62g g (6.96mmol) HClTyrOMe.ESI/MS:516[M+Na]
+, 491[M+H]
+, Rf=0.350 (chloroform/methanol, 15: 1).
2, the preparation of N-(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) tyrosine (4f)
Adopt the operation of step 2 among the embodiment 1, by 1g (2.17mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyltyrosine methyl esters obtains 650mg (67%) title compound, is faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) tyrosine (5f)
Adopting the operation of step 3 among the embodiment 1, by 620mg (1.39mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) tyrosine obtains 450mg (84%) title compound, is faint yellow solid.ESI/MS:380[M+H]
+,
(C=1, ethanol),
1HNMR (300MHZ, DMSO-d6): δ/ppm=2.848 (m, J=9.9Hz, 1H), 3.160 (s, 1H), 3.055 (dd, J=9.6Hz, J=4.8Hz, 2H), 4.235 (m, J=5.6Hz, 1H), 4.353 (m, J=6.2Hz, 2H), 4.448 (s, 1H), 6.702 (d, J=8.4Hz, 2H), 7.009 (t, J=7.2Hz, 1H), 7.023 (t, J=7.8Hz, 1H), 7.145 (d, J=8.1Hz, 2H), 7.377 (d, J=8.1Hz, 1H), 7.444 (d, J=7.5Hz, 1H), 8.979 (d, J=7.5Hz, 1H), 9.354 (s, 1H), 9.861 (s, 1H), 11.192 (s, 1H), 12.9 (s, 1H).
The preparation of embodiment 7.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) proline(Pro) (5g)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-proline methyl ester (3g)
Adopt the operation of step 1 among the embodiment 1, replace 1.07g (6.96mmol) HClAlaOMe 2g (6.33mmol) to get the 2.8g title compound, be faint yellow solid with 1.15g (6.96mmol) HClProOMe.Rf=0.276 (chloroform/methanol, 15: 1).
2, the preparation of N-(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) proline(Pro) (4g)
Adopt the operation of step 2 among the embodiment 1, by 0.5g (1.17mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl proline methyl ester obtains 400mg (83%) title compound, is faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) proline(Pro) (5g)
Adopting the operation of step 3 among the embodiment 1, by 400mg (0.97mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) proline(Pro) obtains 300mg (89%) title compound, is faint yellow solid.ESI/MS:314[M+H]
+,
(C=1, ethanol),
1HNMR (300MHZ, DMSO-d6): δ/ppm=1.965 (m, J=8.7Hz, 2H) 1.973 (m, J=8.7Hz, 2H), 2.834 (t, J=5.6Hz, 1H), 3.160 (s, 1H), 3.682 (s, 1H), 3.763 (d, J=6.3Hz, 1H), 4.261 (m, J=5.4Hz, 1H), 4.358 (m, J=6.3Hz, 2H), 4.721 (s, 1H), 7.031 (t, J=7.5Hz, 1H), 7.122 (t, J=7.8Hz, 1H), 7.384 (d, J=7.5Hz, 1H), 7.513 (t, J=8.4Hz, 1H), 9.861 (s, 1H), 11.134 (S, 1H).
The preparation of embodiment 8.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) halfcystine (5h)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-acthiol-J (3h)
Adopt the operation of step 1 among the embodiment 1, replace 1.07g (6.96mmol) HClAlaOMe 2g (6.33mmol) to get the 2.7g title compound, be faint yellow solid with 1.2g (6.96mmol) HClCysOMe.Rf=0.259 (chloroform/methanol, 15: 1).
2, the preparation of N-(2-N-Boc-1,2,3,4-β-Ka Lin-3-formyl radical) halfcystine (4h)
Adopt the operation of step 2 among the embodiment 1, by 1.0g (2.31mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl acthiol-J obtains 450mg (48%) title compound, is faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) halfcystine (5h)
Adopting the operation of step 3 among the embodiment 1, by 700mg (1.67mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) halfcystine obtains 580mg (98%) title compound, is faint yellow solid.Mp.200-201℃,ESI/MS:286[M+H]
+,
(C=1, ethanol),
1HNMR (300MHZ, DMSO-d6): δ/ppm=2.875 (d, J=6.5Hz, 2H), 3.368 (d, J=6.7Hz, 2H), 4.063 (m, J=6.7Hz, 1H), 4.463 (d, J=5.8Hz, 2H), 4.688 (d, J=5.6Hz, 1H), 7.028 (t, J=7.2Hz, 1H), 7.119 (t, J=7.8Hz, 1H), 7.369 (d, J=7.8Hz, 1H), 7.507 (d, J=7.6Hz, 1H) 9.317 (d, J=7.5Hz, 1H); 9.861 (s, 1H), 11.2185 (d, J=6.3Hz, 1H).
The preparation of embodiment 9.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) methionine(Met) (5i)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-methionine(Met) methyl esters (3i)
Adopt the operation of step 1 among the embodiment 1, replace 1.07g (6.96mmol) HClAlaOMe 2g (6.33mmol) to get the 2.85g title compound, be faint yellow solid with 1.39g (6.96mmol) HClTyrOMe.Rf=0.328 (chloroform/methanol, 15: 1).
2, the preparation of N-(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) methionine(Met) (4i)
Adopt the operation of step 2 among the embodiment 1, by 1g (2.17mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formylmethionine methyl esters obtains 700mg (72%) title compound, is faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) methionine(Met) (5i)
Adopting the operation of step 3 among the embodiment 1, by 600mg (1.34mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) methionine(Met) obtains 370mg (80%) title compound, is faint yellow solid.Mp.186-189℃,ESI/MS:348[M+H]
+,
(C=1, ethanol),
1HNMR (300MHZ, DMSO-d6): δ/ppm=1.435 (m, J=5.5Hz, 2H), 2.509 (m, J=5.7Hz, 2H), 3.388 (d, J=6.4Hz, 2H), 3.462 (m, J=6.5Hz, 1H), 4.393 (d, J=5.4Hz, 2H), 4.08 (d, J=5.5Hz, 1H), 7.033 (t, J=7.8Hz, 1H), 7.116 (t, J=7.5Hz), 7.374 (d, J=7.8Hz, 1H), 7.494 (d, J=7.8Hz, 1H), 9.136 (d, J=5.5Hz, 1H), 9.861 (s, 1H), 11.207 (s, 1H).
The preparation of embodiment 10.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) L-glutamic acid (5j)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-glutamic acid methyl ester (3j)
Adopt the operation of step 1 among the embodiment 1, with 1.47g (6.96mmol) HClGlu (oMe)
2Replace 1.07g (6.96mmol) HClAlaOMe 2g (6.33mmol) to get the 3.00g title compound, be faint yellow solid.Rf=0.500 (chloroform/methanol, 15: 1).
2, the preparation of N-(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) L-glutamic acid (4j)
Adopt the operation of step 2 among the embodiment 1, by 2.8g (5.9mmol) 2-N-Boc-1,2,3, the two methyl esters of 4-tetrahydrochysene-β-Ka Lin-3-carbamylglutamic obtain 2.0g (76%) title compound, are faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) L-glutamic acid (5j)
Adopting the operation of step 3 among the embodiment 1, by 2.0g (4.49mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) L-glutamic acid obtains 1.6g (94%) title compound, is the light green solid.Mp.186-189℃,ESI/MS:346[M+H]
+,
(C=1, ethanol),
1HNMR (300MHZ, DMSO-d6): δ/ppm=2.114 (m, J=5.5Hz, 2H), 2.4025 (t, J=8.1Hz, 2H), 3.313 (d, J=5.1Hz, 2H), 4.222 (m, J=6.5Hz, 1H), 4.503 (d, J=5.4Hz, 2H), 4.481 (d, J=5.5Hz, and 1H) 7.028 (t, J=7.5Hz, 1H), 7.118 (t, J=7.5Hz, 1H), 7.380 (d, J=7.8Hz, 1H), 7.477 (t, J=7.8Hz, 1H), 9.066 (d, J=5.5Hz, 1H), 9.893 (s, 1H), 11.271 (s, 1H), 11.7 (s, 1H), 12.500 (s, 1H).
The preparation of embodiment 11.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) aspartic acid (5k)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-aspartic acid methyl esters (3k)
Adopt the operation of step 1 among the embodiment 1, with 1.37g (6.96mmol) HClAsp (oMe)
2Replace 1.07g (6.96mmol) HClAlaOMe 2g (6.33mmol) to get the 2.80g title compound, be faint yellow solid.ESI/MS:460[M+H]
+, Rf=0.317 (chloroform/methanol, 15: 1).
2, the preparation of N-(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) aspartic acid (4k)
Adopt the operation of step 2 among the embodiment 1, by 700mg (1.53mmol) 2-N-Boc-1,2,3, the two methyl esters of 4-tetrahydrochysene-β-Ka Lin-3-carbamyl aspartic acid obtain 470mg (72%) title compound, are faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) aspartic acid (5k)
Adopting the operation of step 3 among the embodiment 1, by 460mg (1.07mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) aspartic acid obtains 356mg (91%) title compound, is the reddish-brown solid.ESI/MS:332[M+H]
+,
(C=1,DMF),IR(cm
-1):2936,1729,750。
1HNMR(300MHZ,DMSO-d6):/ppm=2.889(d,J=5.3Hz,2H),3.362(d,J=5.2Hz,2H),4.322(m,J=6.5Hz,1H),4.511(d,J=5.4Hz,2H),4.671(d,J=5.5Hz,1H)7.045(d,J=8.1Hz,1H),7.108(d,J=7.8Hz,1H),7.383(d,J=8.4Hz,1H),7.437(d,J=7.3Hz,1H);9.05(d,J=5.5Hz,1H),9.893(s,1H),11.231(s,1H),11.701(s,1H),12.423(s,1H)。
The preparation of embodiment 12.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Histidine (5l)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-Histidine methyl esters (3l)
Adopt the operation of step 1 among the embodiment 1, replace 1.07g (6.96mmol) HClAlaOMe 2g (6.33mmol) to get the 3.00g title compound, be faint yellow solid with 1.43g (6.96mmol) HClHisOMe.ESI/MS:460[M+H]
+, Rf=0.338 (chloroform/methanol, 15: 1).
2, the preparation of N-(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Histidine (4l)
Adopt the operation of step 2 among the embodiment 1, by 450mg (0.96mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl Histidine methyl esters obtains 330mg (76%) title compound, is faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Histidine (5l)
Adopting the operation of step 3 among the embodiment 1, by 320mg (0.77mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) Histidine obtains 258mg (94%) title compound, is yellow solid.ESI/MS:354[M+H]
+,
(C=1,H
2O),
1HNMR(300MHZ,DMSO-d6):δ/ppm=3.188(m,2H),3.353(d,J=5.3Hz,2H),3.501(d,J=5.4Hz,2H),4.371(d,J=5.5Hz,1H)4.727(d,J=5.5Hz,1H),7.036(t,J=7.2Hz,1H),7.133(t,J=7.2Hz,1H),7.369(d,J=7.8Hz,1H),7.509(d,J=7.8Hz,1H),7.596(s,1H),9.116(s,1H),9.395(d,J=7.8Hz,1H),9.893(s,1H),11.250(s,1H)。
The preparation of embodiment 13.N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) tryptophane (5m)
1, the preparation of N-(N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical)-tryptophan methyl ester (3m)
Adopt the operation of step 1 among the embodiment 1, replace 1.07g (6.96mmol) HClAlaOMe 2g (6.33mmol) to get the 3.20g title compound, be faint yellow solid with 1.78g (6.96mmol) HClTrpOMe.FAB/MS:517[M+H]
+, Rf=0.133 (chloroform/methanol, 15: 1)
2, the preparation of N-(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) tryptophane (4m)
Adopt the operation of step 2 among the embodiment 1, by 1.0g (1.83mmol) 2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl tryptophan methyl ester obtains 680mg (70%) title compound, is faint yellow solid.
3, the preparation of N-(1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) tryptophane (5m)
Adopting the operation of step 3 among the embodiment 1, by 660mg (1.19mmol) N-[(2-N-Boc-1,2,3,4-tetrahydrochysene-β-Ka Lin-3-formyl radical) tryptophane obtains 480mg (91%) title compound, is the light green solid.ESI/MS:403[M+H]
+,
(C=1,DMF),
1HNMR(300MHZ,DMSO-d6):δ/ppm=3.186(d,J=5.4Hz,2H),3.521(d,J=5.4Hz,2H),4.347(d,J=5.5Hz,1H)4.667(d,J=5.5Hz,1H),6.986(t,J=7.2Hz,2H),7.442(d,J=7.5Hz,4H),7.521(d,J=7.3Hz,2H),7.599(s,1H),9.015(d,J=7.2Hz,1H),9.813(s,1H),10.965(s,1H),11.149(s,1H),12.901(s,1H)。
The antithrombotic of test example 1 The compounds of this invention is measured
One, test materials
Supply test agent: the sample that the embodiment of the invention is prepared
Control sample: NS (physiological saline), carboline carboxylate (synthetic), acetylsalicylic acid (available from Shandong Xinhua pharmaceutical factory) by laboratory oneself, inventor place
Laboratory animal: male Wistra rat (available from about Department Of Medicine, Peking University laboratory animal portion, body weight 250 grams)
Two, test method and result
Be dissolved in physiological saline before will measuring for test agent.(5.0mg/ml 3ml/kg) after the anesthesia, separates right carotid and left jugular vein to the Wistra rat with vetanarcol.The silk thread that the long prior precision of a 6cm is weighed is placed in the polyethylene tube, after intubate being full of the normal saline solution (50IU/ml) of heparin sodium, an end inserts the left side vein, adds quantitative heparin sodium anti-freezing from an end, and the adding testing compound, insert the right side artery then.Blood flow flows into the left side vein from the right side artery polyethylene tube of flowing through, and takes out with the silk thread of thrombus after 15 minutes and writes down weight in wet base, in moisture eliminator, placed for two weeks with the silk thread of thrombus after, weighing dry weight (seeing Table 1).
Table 1 compound of the present invention is to thrombotic influence
Compound | Wet weight of thrombus (x ± SDmg) | The thrombus dry weight (x ± SDmg) |
NS carboline carboxylate aspirin 5a 5b 5c 5d 5e 5f 5g 5h 5i 5j 5k 5l | 38.67±8.66 31.69±5.72 a 25.95±3.92 a,b 28.97±9.56 a 24.35±7.78 a,b 23.67±6.88 a,b 25.52±9.65 a 32.24±3.18 33.22±5.67 34.34±7.50 21.47±2.92 a,b,c 20.69±5.44 a,b,c 29.03±6.93 a 28.78±7.46 a 26.15±7.23 a | 14.40±2.30 11.62±2.56 4.11±0.99 5.13±1.34 11.67±1.88 4.14±1.77 12.28±3.54 12.14±4.31 4.13±1.53 10.83±5.91 2.55±0.64 2.59±1.55 6.21±2.72 12.34±1.26 7.20±4.91 |
N=12 a) compares p<0.05 with the NS group; B) compare p<0.05 with carboline carboxylate; C) compare p<0.05 with acetylsalicylic acid
As can be seen from the test results, the antithrombotic acitivity of The compounds of this invention obviously is better than control sample, illustrates that The compounds of this invention has very high antithrombotic acitivity.
The external platelet aggregation inhibitory activity of test example 2 The compounds of this invention is measured
One, test materials
1, for test agent: the sample that the embodiment of the invention is prepared
2, control sample: carboline carboxylate (oneself is synthetic), acetylsalicylic acid (available from Shandong Xinhua pharmaceutical factory)
3, laboratory animal: male White Rabbit (available from about Department Of Medicine, Peking University laboratory animal portion, body weight 3000 grams)
Two, test method and result
Rabbit ear edge vein is got blood, with 3.8% Sodium Citrate (V
Sodium Citrate: V
Rabbit blood=1: 9) anti-freezing.Centrifugal 10 minutes of 800-1200g/min platelet rich plasma (PRP), centrifugal 10 minutes again with 3500g/min, platelet poor plasma (PPP).With ADP (adenosine diphosphate (ADP)) is that (final concentration is 10 to the gathering of inductor induced platelet
-5Mmol/l).Test-results sees Table 2.
Table 2 compound of the present invention is to the influence of AD inductive platelet aggregation
Compound | Maximum platelet aggregation-against rate (%) | |
Concentration (10 -4mol/l) | Concentration (10 -5mol/l) | |
Aspirin carboline carboxylate 5a 5b 5c 5d 5e 5f 5g 5h 5i 5j 5k 5l | 18.75 53.12 20.8 26.4 25.3 27.8 25 28 15.8 34.7 46.1 15.6 28.4 | 10.94 40.62 6.25 4.17 18.9 9.38 27.3 95.8 16 24.2 25.3 38.3 4.17 15.8 |
Though carboline carboxylate and amino acid modified thing all do not have a strong platelet aggregation inhibitory activity external as can be seen from the test results, all apparently higher than acetylsalicylic acid, are 10 in concentration
-5The external platelet aggregation inhibitory activity of mol/l The compounds of this invention 5f has reached 95.8%, apparently higher than carboline carboxylate, illustrates that the amino acid modified strategy that the present invention adopts has clear and definite application value.
Claims (10)
1, a kind of carboline carboxylate derivative has the structure of general formula I,
General formula I
Wherein R is selected from :-CH
3,-CH
2C
6H
5,-CH (CH
3)
2,-CH
2OH ,-CH (OH) CH
3,-CH
2C
6H
4-OH-p, Pyrrolidine-2-base ,-CH
2SH ,-CH
2CH
2SCH
3,-CH
2CH
2COOH ,-CH
2COOH, 1,3-imidazoles methyl or indoles-3-methyl.
2, the synthetic method of compound of Formula I may further comprise the steps:
1), L-tryptophane and formaldehyde condensation are made (3S)-β-Ka Lin carboxylic acid,
2), 2 N of (3S)-β-Ka Lin carboxylic acid are protected preparation N-protected base-β-Ka Lin carboxylic acid,
3), with N-protected base-β-Ka Lin carboxylic acid and amino acid ester condensation prepared N-protected base-β-Ka Lin amido-carboxylic acid esters,
4), N-protected base-β-Ka Lin amido-carboxylic acid esters is taken off protecting group and ester is hydrolyzed to acid promptly gets general formula compound of the present invention.
3, according to the synthetic method of claim 2, wherein the condensation reaction in the step 1 is to carry out under mineral acid catalysis.
4, according to the synthetic method of claim 3, wherein said mineral acid is the vitriol oil.
5, according to the synthetic method of claim 2, wherein the protecting group of 2 N of (3S)-β-Ka Lin carboxylic acid is tertbutyloxycarbonyl or benzyl in the step 2.
6, want 5 synthetic method according to right, wherein the protecting group of 2 N of (3S)-β-Ka Lin carboxylic acid is a tertbutyloxycarbonyl in the step 2.
7, want 2 synthetic method according to right, used condensing agent is DCC in the step 3;
8, according to the synthetic method of claim 2, wherein deprotection and ester hydrolysing step are first saponification hydrogenolysis or first saponification acidolysis more again in the step 4.
9, according to the synthetic method of claim 8, wherein deprotection steps is first saponification acidolysis again in the step 4.
10, the purposes of compound of Formula I in the preparation antithrombotic reagent.
General formula I
Wherein R is selected from-CH
3, CH
2C
6H
5,-CH (CH
3)
2,-CH
2OH ,-CH (OH) CH
3,-CH
2C
6H
4-OH-p, Pyrrolidine-2-base ,-CH
2SH ,-CH
2CH
2SCH
3,-CH
2CH
2COOH ,-CH
2COOH, 1,3-imidazoles methyl, indoles-3-methyl.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100742046A CN100494195C (en) | 2004-09-03 | 2004-09-03 | Carboline carboxylate derivative, and its synthesizing method and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100742046A CN100494195C (en) | 2004-09-03 | 2004-09-03 | Carboline carboxylate derivative, and its synthesizing method and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1743326A true CN1743326A (en) | 2006-03-08 |
CN100494195C CN100494195C (en) | 2009-06-03 |
Family
ID=36138873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100742046A Expired - Fee Related CN100494195C (en) | 2004-09-03 | 2004-09-03 | Carboline carboxylate derivative, and its synthesizing method and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100494195C (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101190915B (en) * | 2006-11-30 | 2010-05-12 | 首都医科大学 | Anti-thrombus N-butyl-2,2-dimethyl-4-oxy-tetrahydroimidazopyridoindole and its synthesis and application |
CN101200466B (en) * | 2006-12-15 | 2011-04-20 | 首都医科大学 | Heterocyclic compounds having antithrombotic activity, preparation method and uses thereof |
CN101597291B (en) * | 2008-06-04 | 2011-09-28 | 首都医科大学 | 2-aminoacyl tryptophyl-Beta-tetrahydric carboline-3-carboxylic acid carbobenzoxy as well as preparation method and application thereof |
CN101597290B (en) * | 2008-06-04 | 2011-11-09 | 首都医科大学 | Beta-carboline-3-formyl tryptophyl amine acid carbamate as well as preparation method and application thereof |
CN102234278A (en) * | 2010-04-26 | 2011-11-09 | 首都医科大学 | (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives, and synthesis method and application thereof |
CN102234277A (en) * | 2010-05-07 | 2011-11-09 | 首都医科大学 | Amino-acid-modified 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acids, and synthesis method and application thereof |
CN101200493B (en) * | 2006-12-11 | 2011-11-09 | 首都医科大学 | (3S)-N-(L-aminoacyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, preparation method and uses thereof |
CN102241675A (en) * | 2010-05-14 | 2011-11-16 | 首都医科大学 | (1R,3S)-1-(4-hydroxyl-3-methoxycarboxyl)-1,2,3,4-tetrahydro-beta-carboline-3-formyl amino acid derivatives as well as preparation method and application thereof |
CN102250127A (en) * | 2010-05-19 | 2011-11-23 | 首都医科大学 | Tetrahydro carboline derivative modified with two amino acids and preparation method and application thereof |
CN101591335B (en) * | 2008-05-30 | 2012-04-18 | 首都医科大学 | N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof |
CN102127079B (en) * | 2010-01-15 | 2012-09-19 | 首都医科大学 | Pyrrolo-pyrazin-carboline diketone compounds and preparation method and applications thereof |
CN102796166A (en) * | 2011-05-26 | 2012-11-28 | 首都医科大学 | Glucose-modified 4H-beta-carboline carboxylic acid derivative and preparation method and application thereof |
CN102796098A (en) * | 2011-05-27 | 2012-11-28 | 首都医科大学 | (1S, 3S)-1-1, 3-benzodioxole-1, 2, 3, 4-tetrahydrophthalic anhydride-beta-carboline-3-formyl-amino acid methyl ester, and preparation method and application thereof |
CN103450067A (en) * | 2012-05-29 | 2013-12-18 | 首都医科大学 | Bi[indole-3-yl-acetylamino acid] connected by ethyl, preparation method, antithrombotic function, and applications thereof |
CN103450333A (en) * | 2012-05-29 | 2013-12-18 | 首都医科大学 | 1,1-dimethyl-beta-carboline carboxylic acid-modified RGD peptides and their synthesis, anti-thrombus effect and use |
CN104211700A (en) * | 2013-06-05 | 2014-12-17 | 首都医科大学 | Novel carboline carboxylate analogues, synthesis, nano structure, antitumor activity, and applications thereof |
CN104744460A (en) * | 2013-12-30 | 2015-07-01 | 南开大学 | B-carboline, dihydro-B-carboline and tetrahydro-B-carboline alkaloid derivative as well as preparation method and application in aspects of plant virus prevention and cure, sterilization and insecticide |
CN105273044A (en) * | 2014-06-13 | 2016-01-27 | 首都医科大学 | 1-(ethylamino acid benzyl ester)-beta-carboline-3-benzyl carboxylate, preparation, nano-structure, activity and application |
CN105294826A (en) * | 2014-06-13 | 2016-02-03 | 首都医科大学 | 1-(ethyl-Leu-AA-OBzl)-beta-carboline-3-carboxylate, and preparation, structure and application thereof |
CN105294825B (en) * | 2014-06-10 | 2018-07-27 | 首都医科大学 | Nanostructure, preparation, activity and the application of 1- (ethylamino acid benzyl ester)-B-carboline -3- benzyl carboxylates |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827307B (en) * | 2011-06-17 | 2015-06-17 | 首都医科大学 | Beta-cyclodextrin-modified tetrahydro-beta-carboline carboxylic acid derivatives, and preparation method and application thereof |
CN103450371A (en) * | 2012-06-01 | 2013-12-18 | 首都医科大学 | Tetrahydro-beta-carbolinyl-3-formacyl-diethylenetriamino-beta-cyclodextrins, and preparation, antithrombotic activity and application thereof |
-
2004
- 2004-09-03 CN CNB2004100742046A patent/CN100494195C/en not_active Expired - Fee Related
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101190915B (en) * | 2006-11-30 | 2010-05-12 | 首都医科大学 | Anti-thrombus N-butyl-2,2-dimethyl-4-oxy-tetrahydroimidazopyridoindole and its synthesis and application |
CN101200493B (en) * | 2006-12-11 | 2011-11-09 | 首都医科大学 | (3S)-N-(L-aminoacyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, preparation method and uses thereof |
CN101200466B (en) * | 2006-12-15 | 2011-04-20 | 首都医科大学 | Heterocyclic compounds having antithrombotic activity, preparation method and uses thereof |
CN101591335B (en) * | 2008-05-30 | 2012-04-18 | 首都医科大学 | N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof |
CN101597291B (en) * | 2008-06-04 | 2011-09-28 | 首都医科大学 | 2-aminoacyl tryptophyl-Beta-tetrahydric carboline-3-carboxylic acid carbobenzoxy as well as preparation method and application thereof |
CN101597290B (en) * | 2008-06-04 | 2011-11-09 | 首都医科大学 | Beta-carboline-3-formyl tryptophyl amine acid carbamate as well as preparation method and application thereof |
CN102127079B (en) * | 2010-01-15 | 2012-09-19 | 首都医科大学 | Pyrrolo-pyrazin-carboline diketone compounds and preparation method and applications thereof |
CN102234278A (en) * | 2010-04-26 | 2011-11-09 | 首都医科大学 | (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives, and synthesis method and application thereof |
CN102234277B (en) * | 2010-05-07 | 2012-12-26 | 首都医科大学 | Amino-acid-modified 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acids, and synthesis method and application thereof |
CN102234277A (en) * | 2010-05-07 | 2011-11-09 | 首都医科大学 | Amino-acid-modified 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acids, and synthesis method and application thereof |
CN102241675A (en) * | 2010-05-14 | 2011-11-16 | 首都医科大学 | (1R,3S)-1-(4-hydroxyl-3-methoxycarboxyl)-1,2,3,4-tetrahydro-beta-carboline-3-formyl amino acid derivatives as well as preparation method and application thereof |
CN102241675B (en) * | 2010-05-14 | 2013-06-19 | 首都医科大学 | (1R,3S)-1-(4-hydroxyl-3-methoxycarboxyl)-1,2,3,4-tetrahydro-beta-carboline-3-formyl amino acid derivatives as well as preparation method and application thereof |
CN102250127B (en) * | 2010-05-19 | 2013-06-19 | 首都医科大学 | Tetrahydro carboline derivative modified with two amino acids and preparation method and application thereof |
CN102250127A (en) * | 2010-05-19 | 2011-11-23 | 首都医科大学 | Tetrahydro carboline derivative modified with two amino acids and preparation method and application thereof |
CN102796166B (en) * | 2011-05-26 | 2014-04-02 | 首都医科大学 | Glucose-modified 4H-beta-carboline carboxylic acid derivative and preparation method and application thereof |
CN102796166A (en) * | 2011-05-26 | 2012-11-28 | 首都医科大学 | Glucose-modified 4H-beta-carboline carboxylic acid derivative and preparation method and application thereof |
CN102796098A (en) * | 2011-05-27 | 2012-11-28 | 首都医科大学 | (1S, 3S)-1-1, 3-benzodioxole-1, 2, 3, 4-tetrahydrophthalic anhydride-beta-carboline-3-formyl-amino acid methyl ester, and preparation method and application thereof |
CN102796098B (en) * | 2011-05-27 | 2014-04-16 | 首都医科大学 | (1S, 3S)-1-1, 3-benzodioxole-1, 2, 3, 4-tetrahydrophthalic anhydride-beta-carboline-3-formyl-amino acid methyl ester, and preparation method and application thereof |
CN103450067B (en) * | 2012-05-29 | 2015-01-07 | 首都医科大学 | Bi[indole-3-yl-acetylamino acid] connected by ethyl, preparation method, antithrombotic function, and applications thereof |
CN103450333A (en) * | 2012-05-29 | 2013-12-18 | 首都医科大学 | 1,1-dimethyl-beta-carboline carboxylic acid-modified RGD peptides and their synthesis, anti-thrombus effect and use |
CN103450067A (en) * | 2012-05-29 | 2013-12-18 | 首都医科大学 | Bi[indole-3-yl-acetylamino acid] connected by ethyl, preparation method, antithrombotic function, and applications thereof |
CN103450333B (en) * | 2012-05-29 | 2016-03-30 | 首都医科大学 | The RGD peptide that 1,1-dimethyl-β-carboline carboxylic acid is modified, its synthesis, anti thrombotic action and application |
CN104211700A (en) * | 2013-06-05 | 2014-12-17 | 首都医科大学 | Novel carboline carboxylate analogues, synthesis, nano structure, antitumor activity, and applications thereof |
CN104211700B (en) * | 2013-06-05 | 2016-08-10 | 首都医科大学 | Carboline carboxylate analog, its synthesis, nanostructured, anti-tumor activity and application |
CN104744460A (en) * | 2013-12-30 | 2015-07-01 | 南开大学 | B-carboline, dihydro-B-carboline and tetrahydro-B-carboline alkaloid derivative as well as preparation method and application in aspects of plant virus prevention and cure, sterilization and insecticide |
WO2015101206A1 (en) * | 2013-12-30 | 2015-07-09 | 南开大学 | Β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives and method for preparing same and use in aspects of preventing and treating plant viruses, fungicides and insecticides |
US10208033B2 (en) | 2013-12-30 | 2019-02-19 | Nankai University | β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives and preparation methods same and use in aspects of preventing and treating plant viruses, fungicides and insecticides |
CN105294825B (en) * | 2014-06-10 | 2018-07-27 | 首都医科大学 | Nanostructure, preparation, activity and the application of 1- (ethylamino acid benzyl ester)-B-carboline -3- benzyl carboxylates |
CN105273044A (en) * | 2014-06-13 | 2016-01-27 | 首都医科大学 | 1-(ethylamino acid benzyl ester)-beta-carboline-3-benzyl carboxylate, preparation, nano-structure, activity and application |
CN105294826A (en) * | 2014-06-13 | 2016-02-03 | 首都医科大学 | 1-(ethyl-Leu-AA-OBzl)-beta-carboline-3-carboxylate, and preparation, structure and application thereof |
CN105294826B (en) * | 2014-06-13 | 2018-09-07 | 首都医科大学 | 1- (ethyl-Leu-AA-OBzl)-B-carboline -3- benzyl carboxylates, preparation, structure and application |
Also Published As
Publication number | Publication date |
---|---|
CN100494195C (en) | 2009-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1743326A (en) | Carboline carboxylate derivative, and its synthesizing method and use | |
CN1274713C (en) | Inhibitors of kallikrein | |
CN1169809C (en) | Beta-tetrahydro carboline carboxylic acid, its RGD conjugate, their synthesis and medical application | |
CN1052730C (en) | Compounds with growth hormone releasing properties | |
CN1867322A (en) | Crystalline form of gamma-aminobutyric acid analog | |
CN1100785C (en) | Novel mercaptoacetylamido-1,3,4,5-tetrahydro-benzo[c] azepin-3-one disulfide derivs. useful as inhibitors of enkephalinase and ACE | |
CN1307575A (en) | New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same | |
CN1527814A (en) | Nitric oxide synthase inhibitor phosphate salt | |
CN1441785A (en) | Tetrahydroixoquinoline analogs useful as growth hormone secretagogues | |
CN1948332A (en) | Glycyrrhetinic acid-30-acylamide derivatives and its use | |
CN1950359A (en) | Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IKB kinase inhibitor | |
CN1270518A (en) | Therapeutic or prophylactic agent for glomerulopathy | |
CN1495182A (en) | Substituted diindolyl maleimide for inhibiting cell proliferation | |
CN1048239C (en) | Naphthalene deriv. | |
CN1795183A (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
CN1202895A (en) | Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalluproteinass (MMP) and/or tumour necrosis factor (TNF) | |
CN101817769B (en) | Carbamido peptide aminopeptidase N inhibitor and application thereof | |
CN1090633C (en) | Chlorophyll alpha degraded product metal complex, its preparation method and medicament for anti-gastric ulcer | |
CN1184209C (en) | Chuanxiong alkoxide derivative and its preparation and medicinal composition containing it and use thereof | |
CN101054346A (en) | Preparation method and use for a set of novel compound and composition thereof | |
CN1227538A (en) | Pharmaceutical composition containing 4-oxo-butynic acid | |
CN1037266C (en) | Quinoline derivative fumarates | |
CN1173968C (en) | Production method of halogenated hexahydroxydiphenic derivative and its medicinal application | |
CN1826318A (en) | Stable modifications of tegaserod hydrogen maleate | |
CN1380288A (en) | Tetrahydroisoquinoline hydroximic acid sulfamide compound, its synthesis method and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090603 Termination date: 20140903 |
|
EXPY | Termination of patent right or utility model |